Novel cardiac myosin inhibitor for hypertrophic cardiomyopathy
Journal of General Physiology · 2024
DOI: 10.1085/jgp.202413640 ↗Kurz gefasst
Kommentar in der Zeitschrift Journal of General Physiology, 2024. Verfasst von Danuta Szczesna-Cordary. Beteiligte Einrichtung: Department of Molecular and Cellular Pharmacology, University of Miami, Miller School of Medicine, Miami, FL, USA. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic, Cardiac Myosins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0). Gefördert von: NHLBI NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
New RLC-1 small-molecule inhibits actomyosin interactions, reduces contractile force, and speeds up myosin cross-bridge kinetics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Molecular and Cellular Pharmacology, University of Miami, Miller School of Medicine, Miami, FL, USA.
ORCID-Profile: Danuta Szczesna-Cordary
Förderung
- NHLBI NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Szczesna-Cordary, D. (2024). Novel cardiac myosin inhibitor for hypertrophic cardiomyopathy. Journal of General Physiology. https://doi.org/10.1085/jgp.202413640
Vancouver
Szczesna-Cordary D. Novel cardiac myosin inhibitor for hypertrophic cardiomyopathy. Journal of General Physiology. 2024. doi:10.1085/jgp.202413640
BibTeX
@article{SzczesnaCordary2024,
author = {Szczesna-Cordary, Danuta},
title = {Novel cardiac myosin inhibitor for hypertrophic cardiomyopathy},
journal = {Journal of General Physiology},
year = {2024},
doi = {10.1085/jgp.202413640}
}
EUVIMED